(NASDAQ:CLOV), WILMINGTON, Del., April 21, 2025 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following investor conferences: CFO, Peter Kuipers, will present at the 2025 Bank of America Healthcare Conference on Wednesday, May 14, 2025, at 6:00 p.m. Eastern Time. A live […]

Sight Sciences to Debut OMNI(R) Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio New system features higher viscoelastic capacity and TruSync(TM) technology, engineered to safely synchronize surgical control and precision in implant-free, comprehensive MIGS GlobeNewswire April 21, 2025 MENLO PARK, Calif., April 21, 2025 (GLOBE NEWSWIRE) — Sight Sciences,

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer – Former CEO, Marc Forth, to remain as a member of the Company's Board of Directors – GlobeNewswire April 21, 2025 IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on

Tactile Medical to Release First Quarter of Fiscal Year 2025 Financial Results on May 5, 2025 GlobeNewswire April 21, 2025 MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) — Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal

CarGurus To Report First Quarter 2025 Financial Results GlobeNewswire April 21, 2025 BOSTON, April 21, 2025 (GLOBE NEWSWIRE) — CarGurus, Inc. (Nasdaq: CARG), the No. 1 visited digital auto platform for shopping, buying, and selling new and used vehicles1, announced it will issue a press release reporting financial results for the quarter ended March 31,

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism GlobeNewswire April 21, 2025 The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate for treating ASD in 2026 BOSTON,

Climb Global Solutions Appoints Paul Giovacchini to its Board of Directors GlobeNewswire April 21, 2025 EATONTOWN, N.J., April 21, 2025 (GLOBE NEWSWIRE) — Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb” or the “Company”), a value-added global IT channel company providing unique sales and distribution solutions for innovative technology vendors, today announced that the Company's Board of

Kaltura to Announce Financial Results for First Quarter 2025 on Thursday, May 8, 2025 GlobeNewswire April 21, 2025 NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) — Kaltura (Nasdaq: KLTR), the Video Experience Cloud, today announced it will release its first quarter financial results for the period ended March 31, 2025, before market open on Thursday,

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing Study published in the Journal of Clinical Psychopharmacology GlobeNewswire April 21, 2025 SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the

Regeneron Announces Investor Conference Presentations GlobeNewswire April 21, 2025 TARRYTOWN, N.Y., April 21, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities 2025 Health Care Conference at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 13, 2025 2025 RBC Capital Markets Global Healthcare Conference at 11:00